RPC(SZ:000650) Xin Lang Cai Jing·2025-09-01 03:18Company Overview - Renhe Pharmaceutical Co., Ltd. is located in Nanchang, Jiangxi Province, and was established on December 4, 1996, with its listing date on December 10, 1996 [1] - The company primarily engages in the production and sales of traditional Chinese medicine, Western medicine, raw materials, and health-related products, with a revenue composition of 70.25% from pharmaceuticals, 27.79% from health-related products, and 1.95% from other business products [1] Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% year-on-year [2] - The company has cumulatively distributed 1.962 billion yuan in dividends since its A-share listing, with 770 million yuan distributed over the past three years [3] Stock Market Activity - As of September 1, Renhe Pharmaceutical's stock price increased by 2.09% to 6.35 yuan per share, with a trading volume of 150 million yuan and a turnover rate of 1.80%, resulting in a total market capitalization of 8.89 billion yuan [1] - The stock has seen a year-to-date increase of 13.19%, a decline of 3.93% over the last five trading days, a rise of 6.37% over the last 20 days, and an increase of 14.21% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 21 [1] Shareholder Information - As of June 30, 2025, Renhe Pharmaceutical had 104,400 shareholders, a decrease of 2.76% from the previous period, with an average of 12,748 circulating shares per shareholder, an increase of 2.84% [2] - Major shareholders include Hong Kong Central Clearing Limited, holding 11.4865 million shares, and Southern CSI 1000 ETF, holding 10.3367 million shares, both of which have increased their holdings compared to the previous period [3]